Skip to main content

Table 3 Baseline comparison between patients according to inactive disease criteria (ASDAS – CRP < 1.3)

From: Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

  ASDAS CRP < 1.3 (n = 31) ASDAS CRP ≥ 1.3 (n = 49) P
Male gender 27/31 (87.1%) 39/49 (79.6%) 0.548
HLA-B27 positivity 20/27 (74.1%) 37/42 (88.1%) 0.193
Smoking 4/25 (16.0%) 19/41 (46.3%) 0.016*
Baseline:
 Age, years 32.3 ± 9.9 39.8 ± 11.8 0.004*
 Duration of disease, years 10.6 ± 9.3 14.7 ± 9.8 0.047*
Co-medication:
 NSAID 23/31 (74.2%) 35/49 (71.4%) 1.000
 DMARD 27/31 (87.1%) 37/49 (75.5%) 0.259
 MTX 11/31 (35.5%) 21/49 (42.9%) 0.640
 SSZ 22/31 (70.9%) 22/49 (44.9%) 0.037*
 BASDAI 4.6 ± 2.2 5.8 ± 2.0 0.027*
 BASFI 4.4 ± 2.0 6.2 ± 2.5 0.003*
 BASMI 3.6 ± 2.8 5.0 ± 2.7 0.034*
 ASQol 10.6 ± 5.6 11.2 ± 4.8 0.669
 ASDAS – CRP 3.5 ± 0.9 3.9 ± 1.0 0.126
 CRP (mg/L) 20.3 (9.7, 36.7) 24.6 (14.9, 38.9) 0.664
 ESR (mm/h) 23.0 (10.3, 32.0) 21.0 (12.5, 36.5) 0.650
 1st anti-TNF retention 22/31 (71.0%) 23/49 (46.9%) 0.040*
 Last anti-TNF treatment, weeks 176.9 ± 85.2 182.1 ± 106.2 0.820
  1. Values are expressed as mean (SD), median (quartile) and percentages. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, ASQoL Ankylosing Spondylitis Quality of Life, CRP C Reactive Protein, ESR Erythrocyte Sedimentation Rate, ASDAS Ankylosing Spondylitis Disease Activity Score, DMARD Disease Modifying Antirheumatic Drug, NSAID Non-steroidal Anti-Inflammatory Drug, SSZ Sufasalazine, MTX Methotrexate, *P < 0.05